Eliquis generics to enter and reshape DOAC mkt in SEP

By Moon, Sung-ho

24.09.10 05:10:29

가나다라 0

MOHW notifies the listing of items by 18 domestic companies...at the period of Eliquis’s patent expiry

Pfizer and BMS’s countermeasures against the solid lead being made by Lixiana

From this month (September), numerous generic drugs will be released in the direct-acting oral anticoagulant (DOAC) market.

Following Bayer's Xarelto (rivaroxaban), Pfizer and BMS's Eliquis (apixaban) is also facing its patent expiry.

According to industry sources on the 26th, the Ministry of Health and Welfare recently prepared a notice on the reimbursement listing of 18 pharmaceutical companies' products containing apixaban and began collecting opinions.

When looking at the DOACs that are prescribed in internal medicine hospitals and clinics, Bayer’s Xarelto (rivaroxaban), followed by Boehringer Ingelheim’s Pradaxa (dabigatran), Pfizer and BMS’s Eliquis (apixaban), and

Moon, Sung-ho(lib6983@dailypharm.com)

If you want to see the full article, please JOIN US (click)